Pulmonary Hypertension – Current Treatment – Detailed, Expanded Analysis (US)
Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread, with approved drugs available only for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients. In PAH patients, phosphodiesterase type 5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are most commonly prescribed as first-line treatment, with the more-efficacious prostacyclin therapies used in later lines. Branded therapies dominate the PAH treatment algorithm, and combination therapy is common. Adempas is the only approved therapy for CTEPH patients. PH is a highly lucrative market despite the relatively small patient population.
QUESTIONS ANSWERED
What is the current patient share of branded therapies such as United Therapeutics' Orenitram and Remodulin, Actelion’s Opsumit, and Bayer’s Adempas?
What effect has the launch of Actelion’s Uptravi had on treatment decisions?
What are the anticipated changes in prescribing patterns over the next 12 months?
How are specialists utilizing PAH therapies for the treatment of PH WHO Groups 2-5?
What are U.S. specialists’ attitudes and perceptions regarding diagnosis and treatment of PH?
What are the drivers and constraints determining prescribing practices for PH?
Scope
Geography: United States
Primary Research: Survey of 101 U.S. cardiologists / pulmonologists
Pulmonary Hypertension - Current Treatment - Detailed, Expanded Analysis (US)
Current Treatment Physician Insights - Pulmonary Hypertension - US - June 2019
David Rees, Ph.D.
David Rees, M.Biochem., Ph.D., is a senior analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. He has authored reports on osteoporosis, autosomal dominant polycystic kidney disease, pulmonary hypertension, and type 2 diabetes. Previously, he was a postdoctoral research associate at Imperial College London and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize-winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate degree at the University of Bath.
